tirzepatide surpass SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized The SURPASS 1-5 study as
Description
When appetite and food behaviour shift, associated habits sometimes shift with them
Why is ApoB better than LDL cholesterol
These metabolic improvements were attributed to AMPK activation in the liver and adipose
A clear solution that turns cloudy or discolored should be discarded
Understanding Ozempic: What You Should Know Ozempic, containing the active ingredient semaglutide, is FDA-approved specifically for managing type 2 diabetes
